Physician profile
Michael Maroules
NPI 1134221062
$10,414.91
in general payments reported to CMS, 2019-2025
60 companies · $1,777 in 2025
The $1,777 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $907 · 2020: $1,139 · 2021: $1,755 · 2022: $1,702 · 2023: $1,450 · 2024: $1,685 · 2025: $1,777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,879 · Education: $1,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,878.84 |
| Education | $1,032.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $971.29 | 2019-2025 | Vyloy, Xtandi, Xospata |
| E.R. Squibb & Sons, L.L.C. | $773.02 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Seagen INC. | $646.87 | 2019-2023 | Adcetris, Tukysa |
| Incyte Corporation | $633.61 | 2021-2025 | Jakafi |
| Pfizer INC. | $575.05 | 2019-2025 | |
| Amgen INC. | $523.68 | 2019-2024 | Lumakras, Blincyto, Kyprolis |
| Alexion Pharmaceuticals, INC. | $498.90 | 2019-2025 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $485.81 | 2019-2025 | Lynparza, Calquence, Tagrisso |
| Janssen Biotech, INC. | $469.43 | 2019-2025 | Darzalex, Tecvayli, Erleada |
| Novartis Pharmaceuticals Corporation | $429.98 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $371.92 | 2022-2025 | Fotivda |
| Gilead Sciences, INC. | $364.51 | 2021-2025 | Trodelvy |
| Athenex Pharmaceutical Division, LLC | $350.00 | 2020-2021 | |
| Genentech USA, INC. | $287.39 | 2019-2025 | Itovebi, Rozlytrek, Tecentriq |
| Celgene Corporation | $264.99 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Maroules listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.